To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to revise certain regulations related to infant and toddler beverages, and for other purposes.
- Sponsor
- Rep. Jacobs, Sara [D-CA-51]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Apr 21, 2026
Bottom line
H.R. 8412 aims to clarify labeling for toddler beverages to prevent consumer confusion with infant formula and to better inform parents about ingredients like added sugars, aligning with dietary guidelines.
What it actually does
This bill directs the Food and Drug Administration (FDA) to revise regulations concerning the labeling and naming of beverages marketed for children aged 12 to 36 months. Specifically, it prohibits the use of "infant formula" or "formula" in combination with other terms for these products and mandates descriptive common names, especially if they contain added sugars, nonnutritive sweeteners, or flavorings. It also requires specific disclaimers on labels, including warnings against infant consumption and advice regarding added sugars for children under 24 months, while prohibiting recommended daily intake statements.
Proponents argue
Supporters argue this bill is crucial for public health, as current labeling practices for toddler beverages can mislead parents into believing these products are nutritionally equivalent or necessary alternatives to breast milk or cow's milk for older infants and toddlers. They contend that clearer labeling, especially regarding added sugars and the prohibition of "formula" terminology, will help parents make more informed dietary choices, reduce excessive sugar intake in young children, and align product marketing with established nutritional guidelines.
Opponents contend
Opponents, likely from the beverage industry, might argue that the proposed regulations are overly prescriptive and could stifle innovation or confuse consumers who are already familiar with existing product names. They may contend that current labeling is sufficient and that parents are capable of understanding product differences. Additionally, they might argue that the disclaimers and naming conventions could unfairly stigmatize certain products or impose significant reformulation and relabeling costs on manufacturers, potentially limiting consumer choice.
The bill is very short and clear, making it highly accessible for a quick evaluation by any interested reader.
Section 1(a)(1)
Restricting "Infant Formula" and "Formula" Terms for Toddler Beverages
This provision directs the FDA to revise regulations to prohibit any beverage, other than actual infant formula, that is marketed for children over 12 months old from being identified as "infant formula" or using the term "formula" in combination with any other term. This aims to create a clear distinction between products for infants and those for toddlers.
Supporters argue
Supporters argue this is essential to prevent consumer confusion, as many parents mistakenly believe toddler formulas are necessary for their child's development, similar to infant formula. This clarity helps ensure parents make appropriate nutritional choices.
Critics contend
Manufacturers might argue that the term "formula" is well-understood in the context of toddler products and that prohibiting it could disrupt brand recognition and consumer loyalty, potentially leading to market disadvantages.
Tradeoffs
Balances consumer clarity and public health recommendations against potential industry costs and established marketing practices.
Section 1(a)(2)
Standardizing Common Names and Requiring Health Disclaimers for Toddler Drinks
This provision mandates specific common or usual names for milk-based and non-dairy milk-based beverages marketed for children aged 12 to 36 months, requiring descriptive terms like "milk-based drink" and qualifiers like "sweetened" or "flavored" if applicable. It also requires prominent disclaimers on labels, warning against consumption by infants under 12 months and advising that such beverages are not recommended for children 12-24 months due to added sugars. Additionally, it prohibits statements suggesting a recommended daily intake.
If the Secretary of Health and Human Services (acting through the FDA Commissioner) fails to issue final regulations within two years of the Act's enactment, the proposed regulations issued after one year will automatically become final.
Section 1(b)(3)
Why it matters:This is a standard legislative mechanism to ensure agency action and prevent indefinite delays in implementing mandated regulations. It's buried in the procedural section rather than the substantive policy section.
Case for: Supporters would argue this clause provides a critical enforcement mechanism, ensuring that the FDA acts promptly to implement the public health protections outlined in the bill, preventing bureaucratic inertia from delaying important dietary guidance for young children.
Case against: Critics might argue that this clause could lead to hastily finalized regulations if the FDA faces unforeseen complexities or resource constraints, potentially resulting in less thoroughly vetted rules that could have unintended consequences for industry or consumers.
Estimated impact: Ensures the regulatory changes will occur within a defined timeframe, regardless of potential administrative delays.
The revisions to regulations made pursuant to this Act will only begin to apply three years after the date of enactment.
Section 1(c)
Why it matters:This is a standard practice to provide industry with sufficient time to adapt to new regulations, reformulate products, and redesign labeling. It's a practical implementation detail.
Case for: Proponents would argue that this delayed applicability is a reasonable concession to industry, providing ample time for manufacturers to comply with new labeling and naming requirements without incurring undue financial hardship or market disruption.
Case against: Critics might contend that a three-year delay is too long, prolonging the period during which consumers might be misled by current labeling practices and delaying the public health benefits intended by the bill.
Estimated impact: Provides a significant grace period for industry compliance, delaying the full public health impact of the bill.